COMPARATIVE BIOAVAILABILITY STUDY OF THEOPHYLLINE TABLETS MARKETED IN AUSTRALASIACHARLES BG; RAVENSCROFT PJ; BOCHNER F et al.1980; MED. J. AUST.; ISSN 0025-729X; AUS; DA. 1980; VOL. 2; NO 5; PP. 264-266; BIBL. 11 REF.Article

USE OF AN ERGOT PREPARATION (HYDERGINE) IN THE CONVALESCENT PHASE OF STROKE = UTILISATION D'UNE PREPARATION DE L'ERGOT (HYDERGINE) A LA PHASE DE CONVALESCENCE D'UNE HEMIPLEGIEBOCHNER F; EADIE MJ; TYRER JH et al.1973; J. AMER. GERIATR. SOC.; U.S.A.; DA. 1973; VOL. 21; NO 1; PP. 10-17; BIBL. 18REF.Serial Issue

SALICYLATE METABOLITE KINETICS AFTER SEVERAL SALICYLATESBOCHNER F; GRAHAM GG; CHAM BE et al.1981; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1981; VOL. 30; NO 2; PP. 266-275; BIBL. 19 REF.Article

SINGLE-DOSE PHARMACOKINETICS OF METOCLOPRAMIDEROSS LEE LM; EADIE MJ; HOOPER WD et al.1981; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1981; VOL. 20; NO 6; PP. 465-471; BIBL. 15 REF.Article

THE ELIMINATION OF PHENYTOIN IN MANEADIE MY; TYRER JH; BOCHNER F et al.1976; CLIN. EXPER. PHARMACOL. PHYSIOL.; G.B.; DA. 1976; VOL. 3; NO 3; PP. 217-224; BIBL. 18 REF.Article

DECREASED CAPACITY TO METABOLIZE DIPHENYLHYDANTOIN IN A PATIENT WITH HYPERSENSITIVITY TO WARFARINBOCHNER F; HOOPER WD; EADIE MJ et al.1975; AUSTRAL. NEW ZEAL. J. MED.; AUSTRAL.; DA. 1975; VOL. 5; NO 5; PP. 462-466; BIBL. 22 REF.Article

FACTORS INVOLVED IN AN OUTBREAK OF PHENYTOIN INTOXICATION = FACTEURS EN JEU DANS UNE EPIDEMIE D'INTOXICATION PAR LA PHENYTOINEBOCHNER F; HOOPER WD; TYRER JH et al.1972; J. NEUROL. SCI.; NETHERL.; DA. 1972; VOL. 16; NO 4; PP. 481-487; BIBL. 8REF.Serial Issue

Aspirin for myocardial infarction : clinical pharmacokinetic considerationsBOCHNER, F; LLOYD, J. V.Clinical pharmacokinetics. 1995, Vol 28, Num 6, pp 433-438, issn 0312-5963Article

The absorption and disposition of enoxacin in healthy subjectsSOMOGYI, A. A; BOCHNER, F.Journal of clinical pharmacology. 1988, Vol 28, Num 8, pp 707-713, issn 0091-2700Article

Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?BOCHNER, F; LLOYD, J.Clinical science (1979). 1986, Vol 71, Num 6, pp 625-631, issn 0143-5221Article

MEASUREMENT AND PHARMACOKINETICS OF ACETYLSALICYLIC ACID BY A NOVEL HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAYCHAM BE; ROSS LEE L; BOCHNER F et al.1980; THER. DRUG MONIT.; USA; DA. 1980; VOL. 2; NO 4; PP. 365-372; BIBL. 16 REF.Article

DIPHENYLHYDANTOIN CONCENTRATIONS IN SALIVA = CONCENTRATIONS DE LA DIPHENYLHYDANTOINE DANS LA SALIVEBOCHNER F; HOOPER WD; SUTHERLAND JM et al.1974; ARCH. NEUROL.; U.S.A.; DA. 1974; VOL. 31; NO 1; PP. 57-59; BIBL. 16REF.Article

Therapeutic drug monitoring and patient outcome : a review of the issuesTONKIN, A. L; BOCHNER, F.Clinical pharmacokinetics. 1994, Vol 27, Num 3, pp 169-174, issn 0312-5963Article

The clinician and therapeutic drug monitoring in the 1990sBOCHNER, F; TONKIN, A.Medical journal of Australia. 1993, Vol 158, Num 6, pp 422-426, issn 0025-729XArticle

PREDNISOLONE PHARMACOKINETICS IN ASTHMATIC PATIENTSMAY CS; CAFFIN JA; HALLIDAY JW et al.1980; BRIT. J. DIS. CHEST; GBR; DA. 1980; VOL. 74; NO 1; PP. 91-92; BIBL. 5 REF.Article

GLUTETHIMIDE AND 4-OH GLUTETHIMIDE: PHARMACOKINETICS AND EFFECT ON PERFORMANCE IN MAN.CROW JW; LAIN P; BOCHNER F et al.1977; CLIN. PHARMACOL. THERAPEUT.; U.S.A.; DA. 1977; VOL. 22; NO 4; PP. 458-464; BIBL. 19 REF.Article

EFFECT OF DOSAGE INCREMENT ON BLOOD PHENYTOIN CONCENTRATIONSBOCHNER F; HOOPER WD; TYRER JH et al.1972; J. NEUROL. NEUROSURG. PSYCHIATRY; G.B.; DA. 1972; VOL. 35; NO 6; PP. 873-876; BIBL. 8REF.Serial Issue

Ranitidine and procainamide absorptionSOMOGYI, A; BOCHNER, F.British journal of clinical pharmacology. 1985, Vol 20, Num 2, pp 182-183, issn 0306-5251Article

CIMETIDINE INTERACTION WITH PHENYTOINHETZEL DJ; BOCHNER F; HALLPIKE JF et al.1981; BR. MED. J.; ISSN 0007-1447; GBR; DA. 1981; VOL. 282; NO 6275; PP. 1512; BIBL. 5 REF.Article

INTERMITTENT CUSHING'S DISEASEBOCHNER F; BURKE C; LLOYD HM et al.1979; AMER. J. MED.; USA; DA. 1979; VOL. 67; NO 3; PP. 507-510; BIBL. 34 REF.Article

PRELIMINARY OBSERVATIONS OF THE PHARMACOKINETICS OF METHYLPHENOBARBITONEEADIE MJ; BOCHNER F; HOOPER WD et al.1978; CLIN. EXP. NEUROL.; AUS; DA. 1978 PUBL. 1979; VOL. 15; PP. 131-144; BIBL. 7 REF.Article

BIOAVAILABILITY OF DIGOXIN-HYDROQUINONE COMPLEX: A NEW ORAL DIGOXIN FORMULATION.BOCHNER F; HUFFMAN DH; SHEN DD et al.1977; J. PHARM. SCI.; U.S.A.; DA. 1977; VOL. 66; NO 5; PP. 644-647; BIBL. 30 REF.Article

THE EFFECT OF CERTAIN DRUGS ON THE PLASMA PROTEIN BINDING OF PHENYTOIN.HOOPER WD; SUTHERLAND JM; BOCHNER F et al.1973; AUSTRAL. NEW ZEAL. J. MED.; AUSTRAL.; DA. 1973; VOL. 3; NO 4; PP. 377-381; BIBL. 21 REF.Article

ASPIRIN KINETICS AND PLATELET AGGREGATION IN MANSIEBERT DJ; BOCHNER F; IMHOFF DM et al.1983; CLINICAL PHARMACOLOGY AND THERAPEUTICS; ISSN 0009-9236; USA; DA. 1983; VOL. 33; NO 3; PP. 367-374; BIBL. 22 REF.Article

ASPIRIN PHARMACOKINETICS IN MIGRAINE. THE EFFECT OF METOCLOPRAMIDEROSS LEE LM; EADIE MJ; HEAZLEWOOD V et al.1983; EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY; ISSN 0031-6970; DEU; DA. 1983; VOL. 24; NO 6; PP. 777-785; BIBL. 17 REF.Article